[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"optical-coherence-tomography\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:optical-coherence-tomography":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,60,84,110,136,162,188,214,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100639366","investigating-the-effect-of-caffeine-and-alcohol-on-pupil-dynamics-100639366",false,"NCT07625358","Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics","Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics (PAC)","PAC","Participants must meet the inclusion criteria, as shown below, to participate in this study\n\nInclusion Criteria\n\n1. Age: 30 to 50 years of age\n2. Visual Acuity: Best Corrected Visual Acuity (BCVA) of 0.20 LogMAR or better in both eyes\n3. Ability to provide informed consent: Participants must be able to understand and sign the informed consent form\n4. Ability to consume both caffeine and alcohol: Participants must be willing and able to consume caffeine and alcohol as part of the study\n\nParticipants meeting any of the exclusion criteria, as shown in the table below, will be excluded from participation.\n\nExclusion Criteria\n\n1. Diagnosed ocular conditions: Participants with ocular or ocular movement diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, amblyopia, severe ptosis, or conditions relating to pupils: anisocoria, irregular pupil, Adie tonic, Horner's syndrome, Argyll Robertson pupil, etc. These exclude cataracts, refractive errors, and any ocular condition not affecting vision or ocular movement or obstructing the pupil.\n2. Diagnosed and unresolved neurological conditions:Stroke, unresolved traumatic brain injury, space-occupying lesions in the brain, neuropathies, demyelinating conditions, nerve palsies, etc.\n3. Diagnosed systemic conditions that may restrict the participant from drinking caffeine or alcohol: Hypertension, cardiovascular disease, liver disease, kidney disease, etc.\n4. Medications: Participants taking any medications that may interact with caffeine or alcohol, affect alertness, or cause drowsiness\n5. Previous complex intraocular eye surgery: Participants who have undergone any eye surgery other than uncomplicated refractive surgery.\n6. Pregnancy or breastfeeding: Pregnant or breastfeeding women will be excluded from the study, as caffeine and alcohol can affect the fetus or baby\n7. History of substance abuse: Participants with a history of substance abuse\n8. Allergies or sensitivities: Participants with allergies or sensitivities to caffeine or alcohol\n9. Shift work or having travelled across 2 time zones over the past 2 weeks: This is essential to avoid any impact of sleep deprivation on our outcome measures\n10. Non-consumers or light-consumers of caffeine and alcohol Participants who are light consumers of caffeine or alcohol will be excluded due to higher sensitivity to side effects.\n\nCaffeine: If less than 100 mg of caffeine per week from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\\* Alcohol: If AUDIT-C\\*\\* score less than 1\n\n11- Extremely frequent consumers Participants who are extremely frequent consumers of caffeine or alcohol will be excluded due to potential withdrawal symptoms during the required 18-hour abstinence and possible reduced sensitivity to administered doses.\n\nCaffeine: If more than 400mg of caffeine (e.g., 5 espressos) per day from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\\* Alcohol: If AUDIT-C\\*\\* scores more than 4 for men and more than 3 for women\n\nNote: Participants will complete a history update questionnaire at each laboratory visit to report any changes relevant to the exclusion criteria. If a participant no longer meets the eligibility criteria at any visit after the baseline assessment, the visit will either be rescheduled, if appropriate, or the participant will be withdrawn from the study. Reimbursement will be provided on a prorated basis.\n\n\\*CCQ: Caffeine Consumption Questionnaire\n\n\\*\\*AUDIT-C: Alcohol Use Disorders Identification Test-C",true,"ALL","30 Years","50 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to understand how caffeine and alcohol affect the ocular and physiological systems, especially how the pupil (the aperture in the colored part of the eye) responds to light. It will also test whether these changes can be used to detect recent caffeine or alcohol intake using a portable eye device.\n\nThe main questions it aims to answer are:\n\n1. How does caffeine change pupil responses, eye movements, and other ocular and physiological measurements?\n2. How does alcohol change these same ocular and physiological responses?\n3. Are the effects of caffeine and alcohol different from each other?\n4. Can these changes be used to accurately identify whether someone has consumed caffeine or alcohol?\n\nResearchers will compare caffeine, alcohol, and a placebo (a look-alike drink with no active substance) to see how each affects the ocular and physiological outcomes.\n\nParticipants will:\n\n1. Attend three separate sessions where they will consume caffeine, alcohol, or a placebo (in random order)\n2. Undergo pupillary response evaluation using a handheld device that measures responses to different colored light stimuli\n3. Have their eye movements analyzed\n4. Have retinal and choroidal thickness, blood perfusion, and ocular oxygen levels measured\n5. Have basic body measurements recorded (such as pulse rate and blood pressure)\n6. Complete tests at multiple time points over 2 hours after consumption\n\nThe results of this study may help develop a quick and non-invasive way to detect recent caffeine or alcohol use for clinical and safety purposes.",[29,30,31,32,33,34,35],"Caffeine","Alcohol","Pupillary Response","Eye Movements","Optical Coherence Tomography","Optical Coherence Tomography Angiography","Physiological Responses",[29,30,37,38,39,40,41,42,43,44,45,46],"Pupillary light reflex","Pupillometry","Chromatic pupillometry","Eye movements","Oculomotor function","Optical coherence tomography","Optical coherence tomography angiography","Physiological responses","Machine learning","Non-invasive monitoring","RECRUITING","2026-05-28",{"date":50,"type":51},"2026-06-04","ACTUAL",{"date":53,"type":23},"2026-06-01",{"date":55,"type":23},"2027-11-05",{"name":57,"class":58},"National University of Singapore","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":59},"100505087","to-study-the-effects-of-refractive-surgery-on-oct-measurements-in-the-eye-100505087","NCT05856786","To Study the Effects of Refractive Surgery on OCT Measurements in the Eye","To Study the Effects of Refractive Surgery on Optical Coherence Tomography (OCT) Measurements in the Eye: A Pilot Study","Inclusion Criteria:\n\n1. Patients undergoing refractive surgery\n2. For patients undergoing bilateral eye surgery, the one with higher degree of ametropia will be included.\n\nExclusion Criteria:\n\n1. Astigmatism more than 3 Diopters\n2. Visual acuity worse than 20\u002F25\n3. Patients with unstable visual fixation\n4. Severe Dry Eye","19 Years",{"count":69,"type":23},33,"OBSERVATIONAL","Corrective eye surgeries, such as Lasik, are widely used to correct focusing problems such as myopia, or nearsightedness. Often these patients develop other conditions like myopic maculopathy or glaucoma which require monitoring with optical coherence tomography (OCT). Since OCT is a light-based test and changes the refractive status of the eye (in the cornea or the lens), it can potentially affect the results of the OCT measurements but has not been sufficiently studied. This pilot study aims at studying the potential change in OCT parameters in the eye after undergoing such surgery.",[33,73,74],"Refractive Errors","Myopia","2026-03-17",{"date":77,"type":51},"2026-03-18",{"date":79,"type":51},"2024-06-01",{"date":81,"type":23},"2026-12",{"name":83,"class":58},"University of Nebraska",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":59},"100519171","natural-history-of-coronary-atherosclerosis-100519171","NCT06040073","Natural History of Coronary Atherosclerosis","Natural History of Coronary Atherosclerosis Based on Multimodal Imaging and Physiological Fusion Techniques (NASCENT)","NASCENT","Inclusion Criteria:\n\n* General Inclusion Criteria:\n\n  1. Age ≥18 years\n  2. Acute myocardial infarction ≤ 45 days\n  3. Planned coronary angiography examination or potential interventional treatment\n* Angiographic Inclusion Criteria:\n\n  1. The presence of at least 1 non-flow-restricting lesion (visually estimated diameter stenosis: 30%-80%; QFR \\> 0.80) in any non-infarct related artery with RVD ≥2.5 mm by visual assessment\n\nExclusion Criteria:\n\n* General exclusion Criteria:\n\n  1. Cardiogenic shock\n  2. Pregnant or woman of child-bearing potential\n  3. Life expectancy less than 1 year for non-cardiac causes\n  4. Unable to tolerate contrast agents or anticoagulant\u002Fantiplatelet therapy\n  5. Prior CABG or planned CABG\n* Angiographic exclusion Criteria:\n\n  1. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to QFR or RWS measurement\n  2. An interrogated lesion require surgical bypass grafting\n  3. Unable to judge culprit lesion or infarct-related artery according to current evidence","18 Years",{"count":94,"type":23},125,"The present study sought to explore the predictive value of radial wall strain (RWS, derived solely from angiograms) for coronary artery lesion progression compared with lesion vulnerability assessed by optical coherence tomography (OCT). The lesion progression at 1 year was defined as an increase of ≥20% in diameter stenosis based on quantitative coronary angiography (QCA) evaluation.",[97,98,99,33],"Coronary Artery Disease Progression","Radial Wall Strain","Atherosclerotic Lesion","2024-11-04",{"date":102,"type":51},"2024-11-06",{"date":104,"type":51},"2024-07-07",{"date":106,"type":23},"2026-12-31",{"name":108,"class":109},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":70,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":4},"100537122","d-oct-for-detection-and-subtyping-of-bcc-a-diagnostic-cohort-study-100537122","NCT06273722","D-OCT for Detection and Subtyping of BCC: a Diagnostic Cohort Study","Dynamic Optical Coherence Tomography for Detection and Subtyping of Basal Cell","Inclusion Criteria:\n\n* 18+ years\n* Lesions suspect for non-melanoma skin cancer or premalignancy\n* Patient underwent D-OCT scan and biopsy conform regular care\n\nExclusion Criteria:\n\n* Patient unable to sign informed consent.",{"count":118,"type":23},424,"The current gold standard for diagnosing basal cell carcinoma (BCC) is the histopathological examination of biopsy specimen. However, non-invasive imaging modalities such as optical coherence tomography (OCT) may replace biopsy if BCC presence and its subtype can be established with high confidence. Subtype differentiation is crucial; while superficial BCCs (sBCC) can be treated topically, nodular (nBCC) and infiltrative BCCs (iBCC) require excision. Dynamic OCT (D-OCT) is a functionality integrated within the OCT device, enabling the visualization of vascular structures through speckle variance.\n\nDescriptive studies have unveiled vascular shapes and patterns associated with BCC and its respective subtypes. These findings suggest that D-OCT could contribute to the accuracy of BCC detection and subtyping. Yet comparative clinical studies between OCT and D-OCT are lacking. In the proposed diagnostic cohort study, we aim to assess whether D-OCT assessment is superior to OCT in terms of accuracy for BCC detection and subtyping.",[121,33],"Basal Cell Carcinoma",[123,42,124,125],"Basal cell carcinoma","Imaging","Non-melanoma skin cancer","NOT_YET_RECRUITING","2024-10-23",{"date":129,"type":51},"2024-10-26",{"date":131,"type":23},"2024-11-01",{"date":133,"type":23},"2025-08-01",{"name":135,"class":58},"Maastricht University Medical Center",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":59},"100519444","normative-database-of-healthy-subject-vascular-density-using-spectralis-heidelberg-optical-coherence-tomography-angiography-100519444","NCT06043622","Normative Database of Healthy Subject Vascular Density Using Spectralis Heidelberg® Optical Coherence Tomography Angiography","COPENBASE","Inclusion Criteria:\n\n* Voluntary adult subjects or legal representative consenting for minor or subjects under protection\n* Intra ocular pression ≤ 21mmHg\n* Spherical refraction comprised between - 6 D and +6 D and\u002For axial length between 21 and 26mm\n* Patient affiliated to social security system\n\nExclusion Criteria:\n\n* Ocular diseases: glaucoma, retinal diseases as diabetic retinopathy, age-related macular degeneration, amblyopia, optic neuropathy\n* Diabetes mellitus\n* Uncontrolled hypertension blood pressure (\\> 140\u002F90)\n* Recent ocular surgery (\\\u003C 6 months)\n* Any ophthalmological conditions interfering with a good ocular examination or OCT quality (cataract, corneal opacity …)\n* OCT-A sufficient quality ≥ 25 (0 = bad quality \u002F40 = excellent quality\n* Not consenting patient\n* Pathological situation or handicap avoiding good installation",{"count":144,"type":23},200,[26],"Optical coherence tomography angiography (OCT-A) is a determinant progress to study retinal and choroidal vasculature without using a dye injection. OCT-A yields interesting results in different pathologies such as diabetes mellitus, age-related macular degeneration, hypertension blood pressure, particularly by affecting vascular density. Normative database are necessary to compare OCT-A parameters between patients and controls. However, OCT-A devices from different manufactures may give different values for the same subject. It seems to be obvious that each OCT-A device should have its own normative database. In the literature, OCT-A normative databases are developing using different types of devices, but none is available for Heidelberg OCT-A in Caucasians. The purpose of this project is to create a normative database of retinal microvascularisation using Spectralis Heidelberg optical coherence tomography angiography (OCT-A) ® in normal controls.",[33,34],[149,150,42,43,151,152],"Normative database","Healthy subjects","Heidelberg","Vascular density","2024-09-24",{"date":155,"type":51},"2024-09-26",{"date":157,"type":51},"2023-06-12",{"date":159,"type":23},"2026-09",{"name":161,"class":58},"Centre Hospitalier Universitaire, Amiens",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":24,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":186,"locationsCount":59},"100556116","phase-4-effect-of-pcsk9-inhibitors-on-coronary-atherosclerotic-plaques-derived-from-optical-coherence-tomography-100556116","NCT06520904","Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography","Effect of PCSK9 Inhibitors on Coronary Atherosclerotic Plaques Derived From Optical Coherence Tomography in Patients With Premature Coronary Artery Disease: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Men aged 18-55 years and women aged 18-65 years;\n* CAD patients with coronary angiographically confirmed lesions in ≥2 vessels; at least one vessel was critically diseased (50-70% stenosis level);\n* LDL-C \\>3.4 mmol\u002FL without regular statin therapy or LDL-C \\>1.8 mmol\u002FL after 4 weeks of statin lipid-lowering therapy.\n\nExclusion Criteria:\n\n* Known allergies or contraindications to PCSK9 inhibitors and\u002For statin therapy;\n* Prior use of PCSK9 inhibitors;\n* Prior history of hemorrhagic stroke;\n* Prior coronary artery bypass grafting or coronary intervention;\n* Inability to perform OCT imaging or unclear imaging;\n* Severe renal insufficiency (creatinine clearance \\\u003C 30 mL\u002Fmin);\n* Severe hepatic dysfunction;\n* Baseline triglycerides \\> 5.6 mmol\u002FL;\n* Pregnant or lactating women;\n* Life expectancy not exceeding 1 year;\n* In the judgment of the investigator, unsuitable for this study for any reason.","65 Years",{"count":171,"type":23},396,[173],"PHASE4","The presence of coronary atherosclerotic vulnerable plaque significantly impacts the clinical outcomes of patients diagnosed with coronary artery disease (CAD). However, the influence of PCSK9 inhibitors on stabilizing coronary atherosclerotic plaques in individuals with early-onset CAD, evaluated through optical coherence tomography (OCT), remains inadequately understood. Moreover, there is a notable absence of relevant randomized controlled trials investigating this phenomenon. This current study represents a single-center, randomized, controlled, open-label trial conducted among Asian patients with early-onset CAD. Its principal objective was to explore the effects of PCSK9 inhibitors on coronary atherosclerotic plaque morphology as assessed by OCT.",[176,33],"Coronary Artery Disease",[176,178,179,33],"Lipid-lowering Therapy","PCSK9","2024-08-16",{"date":182,"type":51},"2024-08-19",{"date":184,"type":51},"2024-07-01",{"date":106,"type":23},{"name":187,"class":58},"First Affiliated Hospital of Xinjiang Medical University",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":210,"leadSponsor":212,"locationsCount":59},"100542142","early-phase-1-oct-or-angiography-guided-de-escalation-of-dapt-100542142","NCT06339021","OCT or Angiography Guided De-escalation of DAPT","Evaluation of Neointimal Coverage After Guiding De-escalation of Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention by Optical Coherence Tomography or Angiography of STEMI Patients","Inclusion Criteria:\n\n1. 18 \\~ 85 years old adult patients;\n2. Patients diagnosed with STEMI and undergoing PCI.\n3. Patients able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n1. Prior history of intracranial hemorrhage or ischemic stroke during the past 6 months；\n2. Allergy to aspirin or clopidogrel or ticagrelor;\n3. Occurrence of major adverse cardiovascular event (MACE) within 30 days after undergoing PCI;\n4. Platelet count \\\u003C 50 × 109\u002FL;\n5. Major bleeding during the past 12 months;\n6. Any form of oral, long-term anticoagulation therapy;\n7. Pregnancy or lactation;\n8. Suspected aortic dissection;\n9. Coronary CT-negative patients;\n10. Life expectancy \\\u003C1 year;\n11. Uncontrolled hypertension, systolic blood pressure (SBP) ≥180 mmHg, and\u002For diastolic blood pressure (DBP) ≥110 mmHg;\n12. Comorbid conditions included the presence of any of the following: cardiogenic shock, chronic congestive heart failure with NYHA classes III or IV, left ventricular ejection fraction (LVEF) \\\u003C 35% at transthoracic echocardiography, hypotension with SBP \\\u003C 90mmHg and\u002For DBP \\\u003C 60mmHg, severe arrhythmia (including high-degree AV block, sick sinus syndrome, sustained ventricular tachycardia), severe pulmonary insufficiency, pulmonary embolism, hepatic insufficiency due to non-cardiac causes (ALT or AST more than three times the upper limit of the institution's normal reference ranges), cirrhosis, severe renal failure (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2);\n13. Surgery plan within 30 days;\n14. Psychiatric abnormalities or alcohol dependence;\n15. Patients who are participating in other clinical trials;\n16. Unable to tolerate 1 month of DAPT;\n17. Angiographic triple vessel disease coronary disease;\n18. Other situations judged by the investigators not to be suitable for the clinical trial.","75 Years",{"count":197,"type":23},80,[199],"EARLY_PHASE1","Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.\n\nBased on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation.",[33,202,203,204,205],"Dual Antiplatelet Therapy","Antiplatelet De-escalation","Neointimal Coverage","ST Elevation Myocardial Infarction","2024-03-24",{"date":208,"type":51},"2024-04-01",{"date":208,"type":23},{"date":211,"type":23},"2026-12-01",{"name":213,"class":58},"Shenyang Northern Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":222,"targetDuration":224,"studyType":70,"phases":4,"briefSummary":225,"conditions":226,"keywords":231,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":59},"100481520","optical-coherence-tomography-for-intracranial-atherosclerotic-stenosis-100481520","NCT05550077","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis","Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis: a Prospective Registry Study (OCT-ICAS)","OCT-ICAS","Inclusion Criteria:\n\n* Symptomatic ICAS. Participants with ICAS with a transient ischaemic attack (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours\n* Stenotic degree ≥ 50%, measured by digital subtraction angiography\n* The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)\n\nExclusion Criteria:\n\n* Arteriovenous Malformation\n* Aneurysm",{"count":223,"type":23},400,"12 Months","To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).",[227,33,228,229,230],"Intracranial Atherosclerosis","Plaque, Atherosclerotic","Artery Stenosis","Ischemic Stroke",[33,232,233,234],"Intravascular Imaging","Intracranial Atherosclerotic Stenosis","Percutaneous Transluminal Angioplasty and Stenting","2022-09-21",{"date":237,"type":51},"2022-09-23",{"date":239,"type":51},"2020-03-15",{"date":241,"type":23},"2027-12-31",{"name":243,"class":58},"jiaoliqun",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":24,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":59},"100456965","prospective-evaluation-of-complete-revascularization-in-patients-with-multivessel-disease-excluding-chronic-total-occlusions-100456965","NCT05230446","PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions","PRESENT","Inclusion Criteria:\n\n1. Age ≥ 18 years, ≤85 years\n2. The patient is an acceptable candidate for treatment with a drug eluting stent in accordance with the applicable guidelines on percutaneous coronary interventions, manufacturer's Instructions for Use and the Declaration of Helsinki\n3. Patient indication, lesion length and vessel diameter of the target lesion(s) are according to the 'Instructions for Use' that comes with every Resolute Onyx (Zotarolimus-Eluting stent) system.\n4. The patient is willing and able to cooperate with study procedures and required follow up visits\n5. The subject or legal representative has been informed of the nature of the study and agrees to its provisions and has provided an EC approved written informed consent, including data privacy authorization\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years and \\> 85 years.\n2. Single coronary vessel disease.\n3. No left anterior descending lesion.\n4. Patients in cardiogenic shock.\n5. Patients with STEMI.\n6. Presence of a chronic total occlusion (CTO) defined as coronary lesion with Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 on initial angiography present for more than or equal to 3 months.\n7. Left main coronary artery disease\n8. Patients who cannot give informed consent or have a life expectancy of less than 12 months.\n9. Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or to any of the study medications, including both aspirin and P2Y12 inhibitors.\n10. Patients with an extreme LAD tortuosity imparing OCT catheter advancement\n11. Enrollment in another study with another investigational device or drug trial that has not reached the primary endpoint. The patient may only be enrolled once in the PRESENT study.\n12. Previous coronary artery bypass grafting (CABG).\n13. Patient requiring additional cardiac surgery within 6 months.\n14. Women of childbearing potential who do not have a negative pregnancy test result within 7 days before the procedure, women who are known to be pregnant, or who are breastfeeding.","85 Years",{"count":253,"type":23},609,[26],"This prospective, multicenter, non-randomized, single arm, objective performance goal (OPG) study is designed to evaluate clinical outcomes after complete revascularization by PCI and imaging guidance (OCT) in patients with multivessel coronary artery disease including left anterior descending (LAD) presenting with stable angina, or documented silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS).",[257,258,259,260,176,261,33],"Multi Vessel Coronary Artery Disease","Non-ST Elevation Myocardial Infarction","Unstable Angina","Stable Angina","Percutaneous Coronary Intervention","2022-01-25",{"date":264,"type":51},"2022-02-09",{"date":266,"type":51},"2021-11-18",{"date":268,"type":23},"2027-11-18",{"name":270,"class":58},"Erasmus Medical Center"]